Natural antibodies against α(1,3) galactosyl epitope in the serum of cancer patients;Přirozené protilátky proti α(1,3) galaktosylovému epitopu v séru nemocných s maligními nádory

Epidemiologie, Mikrobiologie, Imunologie

Volumn 63, Issue 2, 2014, Pages 130-133

  Hamanova M ^a   Zdrazilova Dubska L ^b   Valik D ^b   Lokaj, J ^c  

^a Biovendor   (Czech Republic)

^b Oddéleni nukleární medicíny Regionálni centrum aplikované molekulami onkologie Masaryk v onkologický ústav   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

3) galactosyl epitope; Alpha(1; Anti Gal; Cancer immunotherapy; ELISA; Natural antibodies

Indexed keywords

DISACCHARIDE; EPITOPE; GALACTOSE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; POLYACRYLAMIDE; ALPHA-GALACTOSYL EPITOPE; ANTIIDIOTYPIC ANTIBODY; TRISACCHARIDE;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PANCREAS CANCER; QUANTITATIVE ANALYSIS; BLOOD; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; SEXUAL DEVELOPMENT;

ANTIBODIES, ANTI-IDIOTYPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SEX CHARACTERISTICS; TRISACCHARIDES;

EID: 84923375577     PISSN: 12107913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Waldmann TA. Immunotherapy: past, present and future. Nature Med, 2003;9:269–277.
2. Galili U, LeTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunology Today, 1997;18(6):281–285.
3. Tönder O, Natvig JB, Matre R. Antibodies in human sera to rabbit erythrocytes. Immunology, 1967;12:629–637.
4. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J exp Med, 1984;160:1519–1531.
5. Galili U. Anti-Gal: an abundant human natural antibody of multiplepathogeneses and clinical benefits. Immunology, 2013;140:1–11.
6. Galili U. Evolution and pathophysiology of the human natural 7. Castronovo V, Colin C, Parent B, Foidart JM, Mahieu P. Possible role of human anti-gal antibodies in the natural antitumor defense system. J Natl Cancer Inst, 1989;81:212-216.
7. Castronovo V, Colin C, Parent B, Foidart JM, Mahieu P. Possible role of human anti-gal antibodies in the natural antitumor defense system.J Natl Cancer Inst, 1989;81:212-216.
8. Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of α-gal glycolipids induces xenograft, like destruction and conversion of lesions into endogenous vaccines. J Immunol, 2007;178:4676–4687.
9. Tremont-Lukas IW, Avila JL, Hernandez D, Vasquez J, Teixeira GM, Rajas M. Antibody levels against alpha-galactosyl epitopes in sera of patients with squamous intraepithelial lesions and early invasive cervical carcinoma. Gynecol Oncol, 1997;64:207–212.
10. Larkin JMG, Norsworthy PJ, A’Hern RP, Eisen TG, Gore ME, Porter CD. Anti-αGaldependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma Res, 2006;16:157–163.
11. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilema. Trends Immunol, 2009;30:286–292.
12. Fishelson Z, Donin E, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol, 2003;40:109–123.
13. Hellrung DJ, Kisselev S, Link CJ. Co-expression of [alpha] (1,3) galactosyltransferase and Bacillus thurigiensis PIPLC enhances hyperacute rejection of tumor cells. Cancer. Immunol Immunother, 2007;56:25–35.
14. Manches O, Plumas J, Lui G, Chaperot L, Molens JP, Sotto JJ, Bensa JJ, Galili U. Anti-Gal mediated targeting of human B-lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. Haematologica, 2005;90:625–634.
15. Rossi GR, Mantino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes. Cancer Res, 2005;65:10555-10561.
16. Itzkowitz SH, Yuan M, Ferell LD, Palekar A, Kim YS. Cancerassociated alterations of blood group antigen expression in human colorectal polyps. Cancer Res, 1986;46:5976–5984.
17. Chen Z, Qiu X, Gu J. Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Amer J Pathol, 2009;174:1139–1148.
18. Sandrin MS, Vaughan HA, Xing PX, McKenzie IF. Natural human anti Gal(1,3)Gal antibodies react with human mucin peptides. Glycoconj J, 1997;14:97–105.
19. Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1-3) galactosyl epitope Cancer. Immunol Immunother, 2005;54:999–1009.
20. Whalen GF, Sullivan M, Wasseff W, Galili U. Cancer immunotherapy by intratumoral injection of α-gal glycolipids. Anticancer Res, 2012;32:3861–3868.